{
    "organizations": [],
    "uuid": "ccf15cb951f0174b21886f12ae9fd2276c6d1996",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-gemphire-therapeutics-reports-q1-l/brief-gemphire-therapeutics-reports-q1-loss-per-share-of-0-58-idUSASC0A0LE",
    "ord_in_thread": 0,
    "title": "BRIEF-Gemphire Therapeutics Reports Q1 Loss Per Share Of $0.58",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Gemphire Therapeutics Inc:\n* GEMPHIRE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE\n* Q1 LOSS PER SHARE $0.58 * Q1 EARNINGS PER SHARE VIEW $-0.59 â€” THOMSON REUTERS I/B/E/S\n* TOP-LINE RESULTS FROM INDIGO-1 PHASE 2B TRIAL IN SHTG ARE TARGETED FOR Q2 2018 FOLLOWING COMPLETION OF ENROLLMENT IN Q1 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-09T06:46:00.000+03:00",
    "crawled": "2018-05-09T12:13:45.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "gemphire",
        "therapeutic",
        "inc",
        "gemphire",
        "therapeutic",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "provides",
        "corporate",
        "update",
        "q1",
        "loss",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "result",
        "phase",
        "2b",
        "trial",
        "shtg",
        "targeted",
        "q2",
        "following",
        "completion",
        "enrollment",
        "q1",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}